EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial

Gary A Wittert iD, Kristy P Robledo, David J Handelsman, Warrick J Inder iD, Bronwyn G A Stuckey, Bu B Yeap iD, Karen Bracken, Carolyn A Allan, David Jesudason, Alicia Jenkins, Andrzej S Januszewski, Mathis Grossmann iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf060 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Gary A Wittert und 11 weiteren Autor:innen. Beteiligte Einrichtung: Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, SA 5000, Australia. Hauptthemen laut MEDLINE: Testosterone, Diabetes Mellitus, Type 2, Erectile Dysfunction, Sexual Behavior. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Bayer, Lilly.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The combined effects of testosterone treatment and lifestyle intervention on sexual function in men at high risk of type 2 diabetes are unclear.

Objective

To assess the effect of testosterone treatment with a lifestyle intervention in men aged 50 to 74 years at high risk of, or newly diagnosed with, type 2 diabetes (via oral glucose tolerance test).

Design

A secondary analysis of the Testosterone for the Prevention of Type 2 Diabetes trial, a double-blind, placebo-controlled trial conducted across 6 Australian centers.

Interventions

Intramuscular testosterone undecanoate (1000 mg) or placebo, 3 monthly for 2 years alongside a community-based lifestyle program. Main outcomes Sexual function measured using the International Index of Erectile Function (IIEF)-15 questionnaire.

Results

Of 1007 participants, 792 (79%) had complete International Index of Erectile Function-15 data. Baseline domain scores were inversely related to age and waist circumference, but unrelated to serum testosterone or estradiol levels. Testosterone treatment improved all 5 International Index of Erectile Function-15 domain scores, with stronger effects on sexual desire and orgasmic function in older men, and sexual desire in men with higher depression scores. Testosterone had no impact on depression. Independent of treatment, reductions in waist circumference were associated with improved erectile function, and reductions in depression scores correlated with better sexual function. Clinically significant improvement in erectile function and sexual desire occurred in 3% and 10% of men, respectively, and was inversely related to baseline function. Clinically significant improvement improvements in erectile function and sexual desire were greater in younger and older men respectively.

Conclusion

Testosterone treatment enhanced sexual desire and, to a lesser extent, erectile function, particularly in older men and those with higher waist circumference or depressive symptoms. Reduced waist circumference and depression independently improved sexual function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TestosteroneDiabetes Mellitus, Type 2Erectile DysfunctionSexual BehaviorAndrogensHumansMaleMiddle AgedAgedDouble-Blind MethodAustraliaPenile ErectionTreatment OutcomeLife StyleLibido

Stichwörter der Autor:innen

clinical trialdiabetesobesitysexual functiontestosterone

Substanzen

Testosteronetestosterone undecanoateAndrogens

Autor:innen und Institutionen

  • Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, SA 5000, Australia.
  • Department of Endocrinology, The Queen Elizabeth Hospital, Woodville, Adelaide, SA 5011, Australia.
  • NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW 2050, Australia.
  • ANZAC Research Institute, University of Sydney and Department of Andrology, Concord Hospital, Sydney, NSW 2139, Australia.
  • Department of Endocrinology, Princess Alexandra Hospital and the University of Queensland, Brisbane, QLD 4102, Australia.
  • Keogh Institute for Medical Research, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital and Medical School, University of Western Australia, Nedlands, WA 6009, Australia.

ORCID-Profile: Gary A Wittert, Warrick J Inder, Bu B Yeap, Mathis Grossmann

Förderung

  • National Health and Medical Research Council
  • Bayer
  • Lilly
  • University of Adelaide
  • Weight Watchers
  • Sonic Healthcare

Zitieren

APA

Wittert, G. A., Robledo, K. P., Handelsman, D. J., Inder, W. J., Stuckey, B. G. A., Yeap, B. B., Bracken, K., Allan, C. A., Jesudason, D., Jenkins, A., Januszewski, A. S., & Grossmann, M. (2025). Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf060

Vancouver

Wittert GA, Robledo KP, Handelsman DJ, Inder WJ, Stuckey BGA, Yeap BB, et al. Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf060

BibTeX
@article{Wittert2025,
  author = {Wittert, Gary A and Robledo, Kristy P and Handelsman, David J and Inder, Warrick J and Stuckey, Bronwyn G A and Yeap, Bu B and Bracken, Karen and Allan, Carolyn A and Jesudason, David and Jenkins, Alicia and Januszewski, Andrzej S and Grossmann, Mathis},
  title = {Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf060}
}
Kostenlos starten →